Oculis Holding AG (OCS) Free Cash Flow (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Free Cash Flow came in at -$19.6 million in Q1 2026, up 7.12% year-on-year from -$18.3 million in Q1 2025, and up 5.99% quarter-over-quarter from -$20.8 million in Q4 2025.
Oculis Holding AG (OCS) Free Cash Flow (2022 - 2026) Analysis & Trends
Oculis Holding AG's Free Cash Flow history runs 5 years deep, the most recent figure standing at -$19.6 million for Q1 2026.
- On a quarterly basis, Free Cash Flow rose 7.12% year-over-year to -$19.6 million in Q1 2026; TTM through Mar 2026 was -$77.7 million, a 28.08% decrease from a year earlier, with the FY2025 full-year figure at -$79.6 million, down 43.84% from the prior year.
- Free Cash Flow improved to -$19.6 million in Q1 2026 per OCS's latest filing, from -$20.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$5.2 million in Q4 2022 and bottomed at -$21.1 million in Q1 2025.
- The 5-year median for Free Cash Flow is -$15.7 million (2024), against an average of -$15.1 million.
- Across the five-year window, Free Cash Flow tumbled 210.52% in 2023 and rose 24.53% in 2024, its largest moves.
- Year by year, Free Cash Flow stood at -$5.2 million in 2022, then tumbled by 210.52% to -$16.0 million in 2023, then advanced by 24.53% to -$12.1 million in 2024, then sank by 72.3% to -$20.8 million in 2025, then increased by 5.99% to -$19.6 million in 2026.
- Per Business Quant, the three latest OCS Free Cash Flow figures stand at -$19.6 million (Q1 2026), -$20.8 million (Q4 2025), and -$16.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 48.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.58 Mn |
| Mar 31, 2026 | -19.58 Mn |
| Dec 31, 2025 | -20.82 Mn |
| Dec 31, 2025 | -20.82 Mn |
| Sep 30, 2025 | -16.62 Mn |
| Sep 30, 2025 | -16.62 Mn |
| Jun 30, 2025 | -20.67 Mn |
| Jun 30, 2025 | -20.67 Mn |
| Mar 31, 2025 | -21.08 Mn |
| Mar 31, 2025 | -21.08 Mn |
| Dec 31, 2024 | -12.09 Mn |
| Dec 31, 2024 | -12.09 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Mar 31, 2024 | -15.72 Mn |
| Mar 31, 2024 | -15.72 Mn |
| Dec 31, 2023 | -16.01 Mn |
| Dec 31, 2023 | -16.01 Mn |